Judge reverses jury decision over $6.5m Takeda payout


A judge has thrown out the jury’s verdict in a case between Japanese drugmaker Takeda and a US man who claims that the company’s drug caused his bladder cancer.

On 29 April, a jury decided in favour of Jack Cooper, saying that the company didn’t do enough to warn him that Actos (pioglitazone) would increase his risk of bladder cancer. The company was ordered to pay Cooper $6.5 million (£4.2 million) in damages.

However, Takeda appealed to the judge, claiming that there was not enough evidence to directly link Cooper’s cancer to the drug. The judge agreed and nullified the jury’s decision.

The case is the first of over 3300 that have been compiled against the company over bladder cancer claims. In 2011, after reviewing safety data on pioglitazone, the US Food and Drugs Administration (FDA) highlighted a possible but unproven link between the drug and increased risk of bladder cancer. The FDA recommended it not be prescribed to patients with active bladder cancer or history of the disease.

Takeda maintains that it has acted responsibly regarding the safety of Actos, disclosing safety data to regulatory authorities and warning about other side effects, such as heart problems.


Related Content

Missing safety risk emails draw $9bn Actos fine

11 April 2014 Business

news image

Judge finds absence of Takeda documentation in bladder cancer case ‘disturbing’

Judge slashes fines in drug safety case

29 October 2014 Business

news image

Takeda and Eli Lilly’s $9 billion damages in diabetes trial reduced to $38 million

Most Read

Antimicrobial resistance will kill 300 million by 2050 without action

16 December 2014 News and Analysis

news image

UK report says resistance will cost global economy $100 trillion

Cutting edge chemistry in 2014

10 December 2014 Research

news image

We take a look back at the year's most interesting chemical science stories

Most Commented

A bad business

19 December 2014 Critical Point

news image

Targets and assessments can boost productivity at universities – but only if they do not stifle creativity and alienate the...

Chemistry behind the ‘blue man’ unlocked

1 November 2012 Research

news image

Biochemical model suggests that silver ions, not nanoparticles, cause a rare skin complaint